Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001493152-23-013813
Filing Date
2023-04-27
Accepted
2023-04-27 16:15:27
Documents
14
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 form10-ka.htm   iXBRL 10-K/A 462640
2 ex31-03.htm EX-31.03 6599
3 ex31-04.htm EX-31.04 6839
  Complete submission text file 0001493152-23-013813.txt   751826

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lctx-20221231.xsd EX-101.SCH 3236
5 XBRL LABEL FILE lctx-20221231_lab.xml EX-101.LAB 36602
6 XBRL PRESENTATION FILE lctx-20221231_pre.xml EX-101.PRE 23812
8 EXTRACTED XBRL INSTANCE DOCUMENT form10-ka_htm.xml XML 7604
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-12830 | Film No.: 23857099
SIC: 2836 Biological Products, (No Diagnostic Substances)